Blue Shield of California Foundation (BSCF) spearheads the California Technology Assessment Forum (CTAF), which was established to #$%$ new and emerging medical technology. CTAF is one of the preeminent independent medical technology #$%$ment organizations in the country. A multidisciplinary group of medical providers, researchers, ethicists, and consumer advocates work to discuss and formulate positions on the safety and effectiveness of new and emerging technologies. Approximately 15 new technologies are reviewed each year, including devices, procedures and diagnostics.
It is recommended that the use of cell-free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 21 and Trisomy 18 in high risk women meets all "FIVE" CTAF criteria for safety and efficacy and improvement in health outcomes.